Future Of Acadia’s Nuplazid In Alzheimer’s Psychosis Unclear After CRL
Executive Summary
An analyst had suggested that in the event of a thumbs-down from the FDA, the company could end up focusing on other catalysts instead.
You may also be interested in...
Keeping Track: Enhertu, Nubeqa Grow With RTOR; Interchangeable Cimerli And Another Nuplazid CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track: Incyte’s Opzelura Earns First Vitiligo Claim; NDAs From Apellis, Acadia
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Acadia’s Nuplazid Needs Another Study For Alzheimer’s Psychosis, US FDA Panel Says
Advisory committee members cited a litany of shortfalls with efficacy data from two existing studies and say a new Phase III trial is needed in a large, ethnically and racially diverse population of Alzheimer’s disease psychosis patients.